Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during herceptin therapy

E G Slavina; A I Chertkova; T N Zabotina; I P Gan'shina; M R Lichinitser

doi:10.1007/s10517-006-0171-7

Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during herceptin therapy

Bull Exp Biol Med. 2006 Mar;141(3):361-3. doi: 10.1007/s10517-006-0171-7.

Authors

E G Slavina¹, A I Chertkova, T N Zabotina, I P Gan'shina, M R Lichinitser

Affiliation

¹ N. N. Blokhin Russian Cancer Research Center, Moscow.

PMID: 17073160
DOI: 10.1007/s10517-006-0171-7

Abstract

We studied the effect of Herceptin therapy on the population composition of lymphocytes and percentage of CD4+CD25+ cells (regulatory T cells) in breast cancer patients. Herceptin treatment decreased the number of "professional" T suppressors (CD4+CD25+ cells and regulatory T cells) in the peripheral blood.

Publication types

Randomized Controlled Trial

MeSH terms

Adult
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / immunology*
CD4 Antigens / immunology*
Female
Humans
Interleukin-2 Receptor alpha Subunit / immunology*
Middle Aged
T-Lymphocytes / immunology*
Trastuzumab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
CD4 Antigens
Interleukin-2 Receptor alpha Subunit
Trastuzumab